Cited by 273Renin-Angiotensin System StudiesEicosanoids and Hypertension PharmacologyAdipokines, Inflammation, and Metabolic Diseases

The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome

Open access
Putnam, Kelly, Shoemaker, Robin, Yiannikouris, Frederique, Cassis, Lisa A.·2012·American Journal of Physiology-Heart and Circulatory Physiology

Abstract

The renin-angiotensin system (RAS) is an important therapeutic target in the treatment of hypertension. Obesity has emerged as a primary contributor to essential hypertension in the United States and clusters with other metabolic disorders (hyperglycemia, hypertension, high triglycerides, low HDL cholesterol) defined within the metabolic syndrome. In addition to hypertension, RAS blockade may also serve as an effective treatment strategy to control impaired glucose and insulin tolerance and dyslipidemias in patients with the metabolic syndrome. Hyperglycemia, insulin resistance, and/or specific cholesterol metabolites have been demonstrated to activate components required for the synthesis [angiotensinogen, renin, angiotensin-converting enzyme (ACE)], degradation (ACE2), or responsiveness (angiotensin II type 1 receptors, Mas receptors) to angiotensin peptides in cell types (e.g., pancreatic islet cells, adipocytes, macrophages) that mediate specific disorders of the metabolic syndrome. An activated local RAS in these cell types may contribute to dysregulated function by promoting oxidative stress, apoptosis, and inflammation. This review will discuss data demonstrating the regulation of components of the RAS by cholesterol and its metabolites, glucose, and/or insulin in cell types implicated in disorders of the metabolic syndrome. In addition, we discuss data supporting a role for an activated local RAS in dyslipidemias and glucose intolerance/insulin resistance and the development of hypertension in the metabolic syndrome. Identification of an activated RAS as a common thread contributing to several disorders of the metabolic syndrome makes the use of angiotensin receptor blockers and ACE inhibitors an intriguing and novel option for multisymptom treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1152/ajpheart.00796.2011

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Putnam, K., Shoemaker, R., Yiannikouris, F., & Cassis, L. A.
Affiliations
University of Kentucky (US)
Corresponding author
Cassis, Lisa A.
Venue
American Journal of Physiology-Heart and Circulatory Physiology
Published
2012-03-15
Volume
302
Issue
6
Pages
H1219-H1230
ISSN
  • 0363-6135 (ISSN-L)
  • 1522-1539
OpenAlex
W2137543153
Cited by
273
References
125
Citations by year
2026: 10 · 2025: 19 · 2024: 23 · 2023: 17 · 2022: 13 · 2021: 17 · 2020: 16 · 2019: 13 · 2018: 20 · 2017: 18 · 2016: 22 · 2015: 21 · 2014: 25 · 2013: 27 · 2012: 12
FWCI
4.46
Type
journal article
Language
en
Open access
Locations
  • American Journal of Physiology-Heart and Circulatory Physiology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01hl073085-13)
  • National Heart, Lung, and Blood Institute (R01-HL-073085, HL-073085)
  • National Institute of General Medical Sciences (P20GM103527)
  • National Center for Research Resources (P20RR021954)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
renin-angiotensin system, metabolic syndrome, dyslipidemia, hypertension, insulin resistance, impaired glucose tolerance, angiotensinogen, angiotensin-converting enzyme, angiotensin II type 1 receptor, Mas receptor, angiotensin II, cholesterol metabolism, oxidative stress, inflammation, adipocytes, pancreatic islet cells, angiotensin receptor blockers, ACE inhibitors
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Animals, Blood Glucose, Blood Pressure, Homeostasis, Humans, Hypertension, Insulin Resistance, Renin-Angiotensin System, Metabolic Syndrome, Glucose Metabolism Disorders, Angiotensin II Type 1 Receptor Blockers, Dyslipidemias, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review